Atlas Trials

To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.

Clinical trial NCT03658213 · WITHDRAWN

Trial details

NCT number
NCT03658213
Sponsor
AstraZeneca
Status
WITHDRAWN
Phase
Phase 3
Study type
INTERVENTIONAL
Breast Cancer
Start date
2020-03-31
Primary completion
2021-11-04
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.